Clinical Trials Logo

Apraxias clinical trials

View clinical trials related to Apraxias.

Filter by:

NCT ID: NCT03153371 Recruiting - Alzheimer Disease Clinical Trials

Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks

EOAD-Subtype
Start date: April 4, 2016
Phase:
Study type: Observational

This study attempts to identify two types of AD by using clinical and cognitive tasks and brain imaging. The subtypes of AD are separated into a "typical" group (memory loss) and a "variant" group (language, visuospatial, and other cognitive difficulties). Performance on the clinical tasks and brain imaging will be compared among the young-onset Alzheimer's disease group, a late-onset Alzheimer's disease group, and a control group.

NCT ID: NCT03120013 Completed - Clinical trials for Multiple System Atrophy

Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia

CStDCSAtaxia
Start date: February 6, 2017
Phase: N/A
Study type: Interventional

Neurodegenerative cerebellar ataxias represent a group of disabling disorders for which we currently lack effective therapies. Cerebellar transcranial direct current stimulation (tDCS) is a non-invasive technique, which has been demonstrated to modulate cerebellar excitability and improve symptoms in patients with cerebellar ataxias. In this randomized, double-blind, sham-controlled study, the investigators will evaluate whether a two-weeks' treatment with cerebellar anodal tDCS and spinal cathodal tDCS can improve symptoms in patients with neurodegenerative cerebellar ataxia and can modulate cerebello-motor connectivity, at short and long term.

NCT ID: NCT03028324 Terminated - Apraxia Speech Clinical Trials

Transcranial Magnetic Stimulation (TMS) for Primary Progressive Apraxia of Speech (PPAOS)

Start date: August 9, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the influence of transcranial magnetic stimulation (TMS) on speech performance in individuals with primary progressive apraxia of speech.

NCT ID: NCT03020381 Recruiting - Alzheimer Disease Clinical Trials

Gait as Predictor of Dementia and Falls. The Gait and Brain Cohort Study

Start date: December 2007
Phase:
Study type: Observational

Motor slowing and cognitive slowing are more prevalent as we age. Importantly, the presence of both in an older person increases their risk of having dementia by ten times. Currently, there are no clinically meaningful predictors of progression to dementia in people with mild cognitive impairment (MCI). The main hypothesis is that subtle variations in gait while performing a simple cognitive task is a reliable, easy to perform, and feasible methodology to detect those older adults at higher risk of progression to dementia and also, at higher risk of further mobility decline and falls. Rationale. The Canadian population is aging. According to recent estimates, the proportion of the population aged 65 and older will increase rapidly from 13% in 2005 to 25% by 2031. This increase in proportion is accompanied by a considerable amount of disability and subsequent dependency which has major effects on both the quality of life of older adults and their caregivers, and on the Canadian health care system. An important goal of geriatric medicine is to reduce the gap between life expectancy and disability-free life expectancy by reducing disability and dependency in the later years of life. A substantial portion of this disability stems from two major geriatric syndromes: cognitive impairment and mobility limitation. The ultimate manifestations of these syndromes are dementia and falls. Interestingly, these manifestations often coexist in elderly people: falling is a common geriatric syndrome affecting about a third of older adults each year, and dementia affects about a third of Canadians aged 80 and over. Together, dementia and falls are responsible for much of the discomfort, disability, and health care utilization in older adults and each will become more prevalent as older Canadians are expected to number approximately $9 million by 2031. The combined direct cost of dementia and falls for the Canadian Health System is over $4.9 billion per year. Establishing reliable and easy to obtain predictors to accurately identify MCI patients at highest risk of progressing to dementia is essential first, to determine who will benefit from additional and/or invasive testing and second, to implement preventative strategies, including cognitive training, physical exercises, and aggressive vascular risk factors correction to delay progression. Even a modest one-year delay in dementia incidence could save Canada $109 billion over 30 years.

NCT ID: NCT02554513 Completed - Speech Disorders Clinical Trials

Apraxia of Speech: Comparison of EPG Treatment (Tx) and Sound Production Treatment (SPT)

EPG&SPT
Start date: November 2, 2015
Phase: N/A
Study type: Interventional

The purpose of the proposed research is to examine the effects of two treatment approaches on speech production involving speakers with chronic apraxia of speech (AOS) and aphasia. The planned investigation is designed to examine the acquisition, maintenance and generalization effects of each treatment. One approach, electropalatography (EPG) uses visual biofeedback in conjunction with articulatory-kinematic treatment and the other approach, sound production treatment (SPT) is one of the most systematically studied articulatory-kinematic treatments for AOS.

NCT ID: NCT02333305 Completed - Clinical trials for Ataxia-oculomotor Apraxia 1

Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10

AOA1
Start date: June 2013
Phase: Phase 3
Study type: Interventional

We propose a study on Ataxia with oculomotor apraxia type 1 (AOA1) in which Coenzyme Q10 (CoQ10) deficit has been observed. Main objectives of the study are : - To monitor evolution of albumin in patients affected with AOA1 while supplemented with CoQ10 ; - To measure with clinical scales and biological markers efficacy of supplementation on disease evolution. AOA1 is characterised by Hypoalbuminemia. Disease duration is negatively correlated with albumin level. This study aims to understand mechanisms of the disease and our hypothesis is that correction or stabilization of albumin level with CoQ10 supplementation could impact disease evolution. The study is planned from 1 to 2 years supplementation. The CoQ10 is classified as a food supplement and has already been tested in other neurological conditions.

NCT ID: NCT02332915 Completed - Aphasia Clinical Trials

Treatment Intensity - Apraxia of Speech

Start date: May 1, 2015
Phase: N/A
Study type: Interventional

A growing neurorehabilitation literature suggests that intense treatment may be desired to maximize the effects of therapy following neurologic injury. This investigation is designed to facilitate the development of efficacious, clinically applicable treatment for acquired apraxia of speech by examining the effects of intensity of treatment (e.g., 9 hours per week vs. 3 hours per week, while holding total number of sessions constant) with a group of speakers who have chronic apraxia of speech and aphasia.

NCT ID: NCT02307019 Completed - Emotional Stress Clinical Trials

Intervention on Caregivers Caring for Patients Poststroke With Upper Limb Apraxia

CPA
Start date: July 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze the effects of a intervention on a specific health prevention/intervention program aimed at caregivers of mild and moderate patients post stroke with upper limb apraxia in comparison to a control group with a no specific formation in that kind of patients.

NCT ID: NCT02235350 Recruiting - Clinical trials for Stroke, Acute Hemiplegia, Apraxia

Action Observation Treatment (AOT) as a Rehabilitation Tool

AOT
Start date: June 2014
Phase: N/A
Study type: Interventional

Epidemiological studies report that 85% of stroke survivors show hemiparesis and a percentage ranging from 55% to 75% report upper limb functional impairment. Early rehabilitation in stroke patients with motor disorders can be effective to restore the affected function and to improve the performance of daily activities. Up to now, different methods and techniques have been used to recover motor functions in stroke patients. However, none of these has been conclusively proven to be more effective than the others. The clinical benefits induced by motor rehabilitation are closely related to "neuroplasticity". The main aim of the present study is to assess the efficacy of action observation treatment, based on Mirror Neuron System (MNS), in the rehabilitation of upper limb motor functions in acute stroke patients. The study will also aim at assessing neuroplasticity within areas belonging to the MNS through functional magnetic resonance (fMRI).

NCT ID: NCT02199093 Completed - Stroke Clinical Trials

Functional Rehabilitation of Upper Limb Apraxia in Patients Poststroke

Start date: May 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze the effects of a mixed intervention of occupational therapy (rehabilitative and compensatory approach) at home to upper limb apraxia in mild and moderate patients post stroke in comparison to a control group with a traditional health educative protocol.